Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
URGN · against 438 other Healthcare companies of similar size
Ranked #316 of 439 · scores higher than 8% of peers
Bars: peers in each 10-point band of the valuation score124 peers with a valuation score of 0–9, including URGN · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | URGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 427 reported | -5.7% | 1.7% | 22% | 30% | |
| EBITDA yieldHigher is better · 439 reported | -3.7% | 4.5% | 20% | 50% | |
| Free cash flow yieldHigher is better · 199 reported | -9.5% | -0.5% | 22% | 20% | |
| Book yieldHigher is better · 429 reported | -7.9% | 36.3% | 2% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 316 | 2.2B USD | 8 | 23 | |
| 316 | 2.0B USD | 8 | 42 | |
| 316 | 1.3B USD | 8 | 44 | |
| 316 | 1.5B USD | 8 | 39 | |
| 316 | 1.7B USD | 8 | 31 | |
| 316 | 2.2B USD | 8 | 35 | |
| 316 | 1.9B USD | 8 | 42 | |
| 316 | 2.8B USD | 8 | 51 | |
| 316 | 885M USD | 8 | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score